Faron enrolls first patient in Phase 1b/2 BEXAR trial of bexmarilimab plus doxorubicin in metastatic soft-tissue sarcoma
Reuters2026/08/27 06:06- Faron Pharmaceuticals enrolled the first patient in the Phase 1b/2 BEXAR trial of bexmarilimab with doxorubicin in metastatic soft-tissue sarcoma.
- No clinical results have been presented; the study will generate safety data first, then move to a randomized efficacy readout versus doxorubicin alone.
- The program expands bexmarilimab into a first-line solid-tumor setting with limited treatment options, aiming to improve response to standard chemotherapy.
- Trial runs at six hospitals in Spain under MEDSIR sponsorship, led by Vall d’Hebron University Hospital in Barcelona.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
MSC Industrial Direct CFO Robert M. Kuhns files initial beneficial ownership statement
Bank of America plunges 6%! CEO says Q3 trading revenue is flat and investment banking income falls short of expectations
Bank of America CEO Brian Moynihan stated that the bank's trading revenue this quarter will be "relatively flat" compared to the third quarter last year, in contrast to the surge in revenue experienced on Wall Street during the first half of this year. He also expects investment banking fees to be between $1.6 billion and $1.8 billion, falling short of the market's expectation of nearly $2 billion.
Canadian Government Launches CA$1 Billion Fund to Grow Value-Added Food Sector
10-Year Treasury Yield Touches 5%, Pushed by Oil Surge-- WSJ
Crypto prices
More
